Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer.
castration-resistant prostate cancer
enzalutamide
epigenetics
hydralazine
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
07 Aug 2021
07 Aug 2021
Historique:
received:
27
05
2021
revised:
03
08
2021
accepted:
05
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Advanced prostate cancers frequently develop resistance to androgen-deprivation therapy with serious implications for patient survival. Considering their importance in this type of neoplasia, epigenetic modifications have drawn attention as alternative treatment strategies. The aim of this study was to assess the antitumoral effects of the combination of hydralazine, a DNA methylation inhibitor, with enzalutamide, an antagonist of the androgen receptor, in prostate cancer cell lines. Several biological parameters, such as cell viability, proliferation, DNA damage, and apoptosis, as well as clonogenic and invasive potential, were evaluated. The individual treatments with hydralazine and enzalutamide exerted growth-inhibitory effects in prostate cancer cells and their combined treatment displayed synergistic effects. The combination of these two drugs was very effective in decreasing malignant features of prostate cancer and may become an alternative therapeutic option for prostate cancer patient management.
Identifiants
pubmed: 34440180
pii: biomedicines9080976
doi: 10.3390/biomedicines9080976
pmc: PMC8391120
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundação para a Ciência e a Tecnologia
ID : PTDC/MECONC/29030/2017
Organisme : Fundação para a Ciência e a Tecnologia
ID : UID/DTP/0076/POCI-01-0145-FEDER-006868
Organisme : Fundação para a Ciência e a Tecnologia
ID : CEECINST/00091/2018
Organisme : Liga Portuguesa Contra o Cancro
ID : NA
Organisme : European Regional Development Fund
ID : NA
Références
Cancer Med. 2017 Jan;6(1):163-172
pubmed: 27997745
Transl Oncol. 2014 Apr 17;:
pubmed: 24746712
Virol J. 2007 Feb 26;4:18
pubmed: 17324262
N Engl J Med. 2020 Jun 4;382(23):2197-2206
pubmed: 32469184
Transl Androl Urol. 2015 Jun;4(3):365-80
pubmed: 26814148
Eur Urol. 2021 Jul;80(1):71-81
pubmed: 33785255
BMJ. 2003 Oct 25;327(7421):955-60
pubmed: 14576246
Am J Cardiol. 2003 May 8;91(9A):18F-40F
pubmed: 12729848
Sci Rep. 2019 Dec 30;9(1):20271
pubmed: 31889127
Cell Death Dis. 2020 Dec 14;11(12):1068
pubmed: 33318475
J Exp Med. 1940 Nov 30;72(6):747-62
pubmed: 19871058
Cancer. 2008 Mar 15;112(6):1247-53
pubmed: 18293426
Am J Clin Exp Urol. 2021 Feb 15;9(1):101-120
pubmed: 33816699
Mol Cancer Ther. 2016 Nov;15(11):2791-2801
pubmed: 27474149
Mol Cancer Ther. 2018 Sep;17(9):1833-1845
pubmed: 29891491
Cancer Chemother Pharmacol. 2009 Mar;63(4):605-13
pubmed: 18521605
Mol Cancer Ther. 2021 May;20(5):915-924
pubmed: 33632874
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Cancer Res. 2019 Jan 1;25(1):52-63
pubmed: 30224345
J Exp Clin Cancer Res. 2015 May 15;34:46
pubmed: 25971429
Eur J Pharmacol. 2016 May 15;779:138-46
pubmed: 26968484
Prostate. 2014 Jun;74(9):959-69
pubmed: 24740858
Nat Commun. 2020 Jun 10;11(1):2935
pubmed: 32523045
J BUON. 2017 Nov-Dec;22(6):1570-1576
pubmed: 29332354
Cancer Treat Rev. 2017 Mar;54:10-23
pubmed: 28189913
N Engl J Med. 2014 Oct 30;371(18):1755-6
pubmed: 25354111
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
Exp Mol Pathol. 2011 Dec;91(3):768-74
pubmed: 21930124
Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1433-44
pubmed: 25154405
PLoS One. 2012;7(3):e29181
pubmed: 22427797
Oncotarget. 2014 Aug 15;5(15):5950-64
pubmed: 24797896
Mol Cancer Ther. 2020 Apr;19(4):1059-1069
pubmed: 32054790
Int J Oncol. 2012 Aug;41(2):425-32
pubmed: 22614157
Oncotarget. 2016 Apr 19;7(16):21875-86
pubmed: 26942461
J Biochem Mol Toxicol. 2019 Aug;33(8):e22338
pubmed: 30980508
Biochem Biophys Res Commun. 2016 Dec 2;481(1-2):46-50
pubmed: 27833018
Future Oncol. 2020 Dec;16(35):2905-2916
pubmed: 32885994
J Pharmacol Exp Ther. 2019 Dec;371(3):703-712
pubmed: 31582422
J Immunol. 1988 Apr 1;140(7):2197-200
pubmed: 3258330
Eur Urol. 2011 Oct;60(4):753-66
pubmed: 21719191
Cancer Lett. 2017 Nov 1;408:155-163
pubmed: 28826721
Cell Prolif. 2017 Dec;50(6):
pubmed: 28868622
Oncotarget. 2015 Apr 20;6(11):9086-98
pubmed: 25871401
Cancer Lett. 2017 Jan 28;385:108-116
pubmed: 27815035
Eur J Gynaecol Oncol. 2014;35(2):140-2
pubmed: 24772915
ChemMedChem. 2009 May;4(5):792-9
pubmed: 19322801
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):22-36
pubmed: 29282359
Oncol Rep. 2007 Nov;18(5):1321-7
pubmed: 17914592
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):207-12
pubmed: 22420986